<DOC>
	<DOCNO>NCT00156156</DOCNO>
	<brief_summary>The objective study determine long-term safety asoprisnil woman abnormal uterine bleeding associate uterine fibroid .</brief_summary>
	<brief_title>Study Asoprisnil Treatment Uterine Fibroids .</brief_title>
	<detailed_description>No medical therapy currently available long-term treatment abnormal uterine bleeding associate uterine fibroid woman many woman must resort surgery relief . The objective study determine long-term safety two asoprisnil dos ( 10 25 mg tablet ) administer daily woman receive asoprisnil one asoprisnil long-term study ( study C03-062 study M01-391 ) . The safety endpoint study include affect asoprisnil endometrium , ovary , bone ( subset study M01-391 subject ) , lipid profile , adverse event , change baseline lab value vital sign . Some subject receive asoprisnil develop endometrial change . As result , dose prematurely discontinue subject . To ensure safety , subject remain study undergo schedule study procedure . In subject , endometrial change reverse asoprisnil discontinuation .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<criteria>Women complete 12 month active treatment study M01391 Month 12 visit procedure Or complete 18 month active treatment study C03062 Month 18 visit procedure ( 14day interruption dose study C02062 study ) OR could continue previous asoprisnil study , eligible retreatment Otherwise good health Premenopausal base Estrogen FSH level Adequate endometrial biopsy significant histological disorder Agrees use doublebarrier method contraception Any abnormal lab procedure result ( ) studydoctor considers important History bloodclotting disorder History osteoporosis require treatment Any invasive procedure ( ) ( D &amp; C , etc ) polyp confirm surgical invasive procedure uterine fibroid perform previous asoprisnil study Hemoglobin &lt; 8.0 g/dL Endometrial thickness â‰¥ 19 mm</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Symptomatic Uterine Fibroids</keyword>
	<keyword>Excessive Uterine Bleeding</keyword>
	<keyword>Uterine Hemorrhage</keyword>
</DOC>